News & Updates

Cognitive-behavioural smoking cessation treatment (treatment as usual [TAU]) coupled with approach bias modification (ApBM) does not appear to be any better than TAU plus sham training or TAU only, a recent study has shown.

A review of 19 meta-analyses shows mixed results on the effects of multivitamin and mineral (MVM) supplementation on health outcomes.

Radioligand therapy, which uses prostate-specific membrane antigen (PSMA)–targeted agents to deliver tumour‑focused radiation, has become a key treatment for metastatic castration‑resistant prostate cancer (mCRPC). At an industry‑sponsored meeting, Professor Kim-Nguyen Chi of the University of British Columbia in Vancouver, Canada, discussed how PSMA-targeted radioligand therapy, specifically lutetium 177–PSMA 617 (¹⁷⁷Lu-PSMA-617), is reshaping mCRPC management and optimizes outcomes.

BTK inhibition with rilzabrutinib does not appear to significantly decrease the incidence of loss-of-asthma-control (LOAC) event compared with placebo in patients with moderate-to-severe asthma with uncontrolled symptoms, according to a phase II study. However, the investigational drug has been associated with meaningful symptom improvements over time, despite withdrawal of background therapy.

Palliative care delivered by hepatologists yields similar improvements in quality of life (QoL) of patients with end-stage liver disease (ESLD) and is associated with greater patient satisfaction compared with palliative care delivered by specialists, according to a study.

A secondary bladder cancer (SBC) rarely occurs among patients with localized prostate cancer who have been treated with radiotherapy (RT), but the incidence rate is not insignificant, reports a study presented at EAU 2026. When it does appear, it usually becomes the primary cause of death in this population.

People exposed to air pollution for too long are at greater risk of developing rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), with the effect potentially modified according to MUC5B rs35705950 genotype, reveals a study.

Interleukin (IL)-6 inhibition with vamikibart is safe and well tolerated and helps improve clinical outcomes in patients with uveitic macular edema (UME), as shown in the phase I DOVETAIL nonrandomized clinical trial.